surmount-osa tirzepatide results In a prespecified secondary analysis of the trial it was found that improves cardiometabolic outcomes in patients with moderate-to-severe OSA and obesity SURMOUNT-OSA findings demonstrate benefit of

Major Weight Loss Results In a Phase 2 clinical trial with 338 adults, participants on the highest dose lost an average of 24.2% of their body weight in 48 weeks

Wilkins et al., 2015)

The FDA is also monitoring the availability of other GLP-1 medications, including dulaglutide and liraglutide, which remain in shortage.) (UPDATE 10/14/24: In a court filing on the 11th the FDA stated they would allow compounding pharmacies to continue to produce compounded tirzepatide medications while it reviewed whether there was a shortage of the active ingredient

If you are taking a medication like Ozempic, Wegovy, or Mounjaro, dont hesitate to reach out to Dr

PMID 17191896